Industry Overview

European drug discovery informatics market was valued at $1,029.9 million in 2025 and is projected to reach $1,967.4 million by 2035, growing at a CAGR of 6.7% during the forecast period (2026–2035). The European Drug Discovery Informatics market is growing steadily as pharmaceutical companies, biotech firms, and research institutions increasingly prioritize data-driven R&D. Rising complexity in drug development and the need for faster, more accurate decision-making are driving adoption of advanced informatics platforms across the region. Investments in digital transformation, coupled with strong government and EU-level support for research innovation, are accelerating the use of tools such as molecular modeling, docking, sequencing analytics, and AI-enabled discovery engines. Collaborative research ecosystems linking academia, industry, and technology providers are further boosting demand for integrated, cloud-based solutions that enhance workflow efficiency.

Market Dynamics

Growing Integration of Informatics Across Pharmaceutical R&D and Academic Research

The European Drug Discovery Informatics market is experiencing strong momentum as pharmaceutical companies, biotech startups, and academic institutions increasingly adopt digital tools to accelerate R&D. Rising pressure to improve clinical success rates and reduce development timelines is driving the deployment of informatics platforms for molecular modeling, docking, sequencing analysis, and data management. Research universities and public research organizations are expanding collaborations with industry, leveraging informatics solutions to support early-stage target identification and drug design. Stricter regulatory expectations around data integrity, reproducibility, and traceability are further pushing organizations to modernize their R&D workflows. Government-backed funding programs such as Horizon Europe are also enabling broader adoption of advanced computational platforms. Collectively, these factors are contributing to sustained growth of the drug discovery informatics market across the region

Shift Toward AI-Driven Platforms and Cloud-Native R&D Workflows

Technological advancement is emerging as a central driver in Europe’s Drug Discovery Informatics market, with rapid adoption of AI, machine learning, and cloud-based computational tools. AI-powered molecular modeling, predictive analytics, and generative design platforms are being integrated to enhance accuracy, reduce iteration cycles, and speed up candidate optimization. Cloud-native architectures enable real-time data sharing, scalable computing, and seamless collaboration across distributed R&D teams. European pharmaceutical and biotech companies are increasingly investing in high-performance computing, real-world data analytics, and advanced visualization tools to support complex biological and chemical datasets. Regulatory agencies such as the EMA are also encouraging digital approaches that strengthen data transparency and quality. These advancements are accelerating the shift toward intelligent, automated, and more efficient drug discovery workflows making technological innovation a key catalyst for market expansion in Europe.

Market Segmentation

• Based on the function, the market is segmented into docking, molecular modeling, libraries & database preparation, sequencing & target data analysis, and others.
• Based on the end-user, the market is segmented into pharmaceutical & biotechnology companies, contract research organizations, and others.

Docking Tools Strengthening Their Position in Europe’s Informatics Landscape

Within Europe, the docking segment continues to gain prominence as research institutions and pharmaceutical developers expand their reliance on simulation-based screening methods. European discovery teams are using docking platforms to refine molecular interactions with greater precision, allowing for faster narrowing of hit candidates and more efficient use of laboratory resources. The region’s strong focus on structural biology and computational chemistry further supports the integration of advanced scoring models and AI-enhanced docking workflows. As collaborative research networks grow across countries such as Germany, the U.K., France, and the Netherlands, demand for high-performance docking solutions remains a central component of the regional informatics ecosystem. This sustained adoption underscores the segment’s leading role within Europe’s overall market structure

Pharmaceutical and Research Institutions Driving Steady Market Expansion

Europe’s pharmaceutical companies, academic institutions, and public research organizations continue to be major contributors to the growth of the region’s drug discovery informatics market. The emphasis on evidence-based development, supported by strong regulatory frameworks and well-funded scientific programs, is encouraging broader use of modeling, data analytics, and integrated informatics platforms. As research priorities expand into fields such as rare diseases, immunology, and advanced biologics, the need for sophisticated computational tools becomes increasingly critical. Ongoing digital transformation across European research facilities is also improving interoperability and data management, allowing teams to adopt more advanced discovery workflows. Combined, these factors reinforce the pivotal role of European life-science stakeholders in shaping steady, long-term market development

Regional Outlook

European drug discovery informatics market is further divided by countries, including the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe.

Germany Dominates the Market with Major Share

Germany holds a strong position in the Drug Discovery Informatics market as research institutions, biotechnology clusters, and pharmaceutical companies continue to expand their use of advanced computational tools. The country’s well-established life-science ecosystem, supported by government funding programs and collaborative research networks, is driving broader integration of modeling, analytics, and AI-enabled platforms across discovery pipelines. Demand is rising in areas such as precision medicine, oncology, and biologics, where data-intensive workflows require sophisticated informatics capabilities. Technology providers are also introducing refined solutions tailored to Germany’s high research standards, improving efficiency and data reliability. As infrastructure upgrades and digital-transformation initiatives progress, adoption of informatics solutions is expected to grow further. Together, these elements reinforce Germany’s leading share in the European market.

Market Players Outlook

The major companies operating in the European drug discovery informatics market include Dassault Systèmes SE, Eurofins Scientific SE, Evotec SE, PerkinElmer, Inc., Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In October 2025, a consortium led by Bristol Myers Squibb and Takeda Pharmaceuticals together with Astex Pharmaceuticals, AbbVie and Johnson & Johnson announced that they will pool thousands of proprietary proteins–small molecule structure datasets to train an advanced AI model under the umbrella of the AI Structural Biology Network. The effort, managed via a federated-data sharing platform by European firm Apheris, aims to improve accuracy in predicting protein–ligand interactions, thereby accelerating early-stage drug discovery across the region.
• In November 2025, major European player Merck KGaA signed a high-value agreement (over US$ 3 billion) with U.S.-based Valo Health to leverage Valo’s AI-driven drug discovery platforms for development of therapies targeting neurodegenerative diseases such as Parkinson’s. This collaboration underscores the growing reliance on AI-powered informatics by traditional European pharmaceutical firms.
• In September 2025, Eli Lilly introduced a new AI and machine-learning drug discovery platform named TuneLab, aiming to make advanced predictive models accessible to smaller biotech firms and research groups. While Eli Lilly is U.S.-based, this development has significant implications for the European informatics market as it increases the availability of state-of-the-art tools and encourages adoption across global R&D networks.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the European drug discovery informatics market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.